TSA campaign to make sure everolimus for TSC-related epilepsy is funded in England In March 2018 NHS England recognised that there is sufficient evidence to commission everolimus for TSC-related epilepsy, which could benefit up to 1,300 people living with TSC. However, in July NHS England

  This is a statement from Tuberous Sclerosis Australia released today (22 August 2018):   We are pleased to share news that Everolimus (Afinitor) for epilepsy has been given a positive recommendation by the pharmaceutical benefits advisory committee (PBAC). This is a recommendation to the

PLEASE NOTE THAT THE SIBLINGS GROUP HAS NOW BEEN CANCELLED. As you may have heard, our annual TSA Big Day event will be taking place this year at Sheffield Hallam University on 10 November 2018. As in previous years, we are providing childcare for those